Glioblastoma (GBM) resistance to the standard of care is prompting scientists to develop better targeted therapeutic strategies. Autophagy is one of the many signaling mechanisms that regulate tumor regrowth. Despite the extensive in vitro and in vivo studies published, knowledge on autophagic modulation remains scarce. This hinders the development of novel treatment modalities that employ autophagic mechanisms for the clinical benefit of patients with GBM. Clinical trials for GBM continue to fall short of showing significant survival or clinical benefit, with the complex glioma heterogeneity often being the reason to blame. Here, we propose that a combination therapy of current antiglioma regimens and autophagic mediators or suppressors can allow us to overcome GBM regrowth in the context of tumor heterogeneity.

中文翻译：

---

编辑神经胶质瘤中的细胞保护性自噬：治疗潜力尚未实现。

胶质母细胞瘤（GBM）对护理标准的抵抗力促使科学家们开发出更具针对性的治疗策略。自噬是调节肿瘤再生的许多信号传导机制之一。尽管已经发表了广泛的体外和体内研究，但是关于自噬调节的知识仍然很少。这阻碍了采用自噬机制为GBM患者提供临床益处的新型治疗方式的发展。GBM的临床试验仍未能显示出显着的存活率或临床获益，复杂的神经胶质瘤异质性通常是造成这种情况的原因。在此，我们建议将目前的抗神经胶质瘤疗法与自噬介体或抑制剂结合使用，可以使我们在肿瘤异质性的背景下克服GBM的再生长。